Highlights of the 67^th ASH Annual Meeting on January 20^th at 14.00 CET

December 2025 - Join us for our next iCMLf Conversation on Tuesday, January 20^th 2026 at 14.00 Central European Time where two international experts will review and discuss the most important biological and clinical updates presented during the the 67th ASH Annual Meeting. 

Whether you attended the conference or not, this session will summarise biological and clinical highlights and will share the most important takeaways for the CML community.

📅 Date: Tuesday, January 20^th
🕑 Time: 14:00 CET
🖥️ Format: Live webinar on Zoom

Read more

December 2025 - Each year, we honour exceptional achievements in CML research and management by recognising lifetime contributions through the three iCMLf Prizes. Since their introduction, these awards have celebrated the work of remarkable scientists, clinicians, and advocates whose leadership, innovation, and dedication have shaped the global CML landscape. 

We invite you once again to participate in this tradition by nominating outstanding individuals whose work has transformed our understanding of CML biology, advanced patient management, or improved access to treatment worldwide. Let’s spotlight the visionaries whose contributions continue to inspire the global CML community.

Read more

December 2025 - We're bringing you highlights from the 67th ASH Annual Meeting with a summary of selected scientific sessions on CML, a prospective study testing nilotinib vs. imatinib with early switch to improve TFR, and the first prospective trial of asciminib with dose escalation as second-line therapy.

🌟 Oral Abstract Session: CML clinical & epidemiological - Therapeutic agents to enhance patient outcomes

Chairs: Elisabetta Abruzzese (Rome) - Vivian Oehler (Seattle)
This clinical session presented major advances in novel TKIs, frontline optimisation strategies, real-world outcomes in blast-phase CML, and next-generation approaches to achieving deeper and safer molecular responses. Across six presentations, investigators showcased: promising phase 1 data for TERN-701 and TGRX-678, updated results from a frontline asciminib combination trial, the largest US analysis of blast-phase management, a prospectie study testing nilotinib vs. imatinib with early switch to improve TFR, and the first prospective trial of asciminib with dose escalation as second-line therapy. 

Collectively, the studies demonstrated:

• High efficacy and favourable safety of new agents even in heavily pretreated or T315I-mutated patients,
• Asciminib’s expanding role in both frontline combinations and second-line therapy,
• The persistent challenge and therapeutic needs of blast-phase CML,
• The importance of risk-adapted frontline selection to improve long-term TFR outcomes,
• And the feasibility of dose escalation strategies with asciminib to address suboptimal responders.

Our key takeaways from the presentations:

Read more

December 2025 - The iCMLf Forum at ASH 2025 brought together global leaders in CML to examine unresolved clinical controversies, emerging biological insights, and the bold scientific ambition to cure CML. As in previous years, the Forum provided a candid, interactive space where guidelines, real-world practice, and future research priorities were openly debated.

Setting the Scene: Collaboration, Innovation, and the Road Ahead

“We hear from a lot of people that CML is ‘done’ and research investment is no longer needed. But what we hear from our programs is very different.”
Nicola Evans (Chief Executive iCMLf)

Opening the meeting, Professor Andreas Hochhaus and Nicola Evans, Chief Executive of the iCMLf, reflected on the Foundation’s global mission and evolving priorities. While CML outcomes have been transformed by 25 years of TKI therapy, speakers emphasised that CML is not ‘done’. Late presentations, TFR failure, pediatric challenges, diagnostic gaps, and inequities in access, particularly in low- and middle-income countries, remain pressing realities. These lived challenges continue to shape the iCMLf’s education, research, and support programs worldwide.

Read more